Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

Applied Health Economics and Health Policy

Volumn 7, Issue 2, 2009, Pages 91-108

  Earnshaw, Stephanie R ^a   Graham, Jonathan ^a   Oleen Burkey, Merrikay ^b   Castelli Haley, Jane ^b   Johnson, Kenneth ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b Teva Neuroscience Inc ^*  (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; REMISSION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MARKOV CHAINS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 70149119967     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/bf03256144     Document Type: Article

References (59)

1. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007; 13 (1): 44-52
2. National Multiple Sclerosis Society. National MS Society information sourcebook [online]. Available from URL: http://nationalmssociety.org/ sourcebook.asp [Accessed 2007 Nov 1]
3. Mayr WT, Pittock SJ, McClelland RL, et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61 (10): 1373-1377
4. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002; 58 (1): 136-138
5. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005; 11 (2): 232-239
6. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000; 6 (2): 91-98
7. O'Brien an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3 (1): 17
8. Orlewska E, Mierzejewski P, Zaborski J, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 2005; 12 (1): 31-39
9. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006; 66 (11): 1696-1702
10. Lundy J, Craig BM. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of Medicare Part D: analysis of claims data from the medicare current beneficiary survey. Clin Ther 2006; 28 (1): 140-145
11. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4 (5): 419-425
12. Kobelt G, Jonsson L, Fredrikson S. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ 2003; 4 (1): 50-59
13. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002; 5 (1): 44-54
14. Iskedjian M, Walker JH, Gray T, et al. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler 2005; 11 (5): 542-551
15. Bose U, Ladkani D, Burrell A, et al. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis: first estimates. J Med Econ 2001; 4: 207-219
16. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998; 2 (4):
17. Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004; 7 (5): 554-568
18. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007; 13 (3): 245-261
19. Chilcott J, McCabe C, Tappenden P, et al., on behalf of the Cost Effectiveness of Multiple Sclerosis Therapies Study Group. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Br Med J 2003; 326: 1-6
20. Sweet BV. Natalizumab update. Am J Health Syst Pharm 2007; 64 (7): 705-716
21. RxList.com. Tysabri (natalizumab) product description [online]. Available from URL: http://www.rxlist.com/cgi/generic/tysabri.htm [Accessed 2007 Apr 2]
22. Polman CH, ized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910
23. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharma-coeconomics 2008; 26 (7): 617-627
24. Biogen I. Natalizumab (Tysabri ®) for the treatment of of managing adults with highly active relapsing remitting multiple sclerosis. Biogen Idec single technology appraisal (STA) submission to the National Institute for Health and Clinical Excellence [online]. Available from URL: http://guidance. nice.org.uk/page.aspx?o=419040 [Accessed 2007 Apr 11]
25. Tappenden P, Chilcott J, effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis. Final report to the National Institute for Clinical Excellence. Centre for Bayesian Statistics in Health Economics. Sheffield: University of Sheffield, 2001 Jul
26. Tappenden P, McCabe C, Simpson E, et al. The clinical and cost-effectiveness of beta interferons and glatiramer acetate in the management of relapsing/remitting and secondary-progressive multiple sclerosis. Report to the Centers for Medicare and Medicaid on behalf of the US Agency for Healthcare Research and Quality. Sheffield: University of Sheffield, 2005 Dec
27. Oleen-Burkey M, Kobelt G, Borgstrom F. Costs and quality of life of patients with relapsing-remitting multiple sclerosis currently on immunomodulatory therapy in the United States [presentation]. International Committee on Databases in Multiple Sclerosis 2003 Conference; 2003 May 30; San Diego (CA)
28. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain 1989; 112 (Pt 1): 133-146
29. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116 (Pt 1): 117-134
30. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: II. Predictive value of the early clinical course. Brain 1989; 112 (Pt 6): 1419-1428
31. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987; 14 (3): 255-261
32. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis: implications for clinical trials. Arch Neurol 1989; 46 (10): 1107-1112
33. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933
34. Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neuro-virol 2001; 7 (4): 386-390
35. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45 (7): 1268-1276
36. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12: 309-320
37. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-1532
38. Gold M, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
39. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50 (3): 701-708
40. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 Mar 2; 354 (9): 911-923
41. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381
42. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multi-focal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374
43. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-8
44. US Department of Labor, Bureau of Labor Statistics. Consumer price index: all urban consumers (current series) [online]. Available from URL: http://data.bls.gov/PDQ/outside.jsp?survey=cu [Accessed 2007 Jun 13]
45. RxList.com. Copaxone (glatiramer acetate) product description [online]. Available from URL: http://www.rxlist.com/cgi/generic/glatiramer.htm [Accessed 2007 Apr 2]
46. Red Book for Windows [computer program]. Windows Version 61129, Vol.44. Montvale (NJ): Thomson PDR, 2007
47. US Department of Health and Human Services. Tysabri risk minimization action plan: summary of TOUCH [online]. Available from URL: http://www/fda/gov/ cder/drug/infopage/natalizumab/RiskMAP.pdf [Accessed 2007 Apr 9]
48. US Department of Health and Human Services, Agency for Healthcare Research and Quality. HCUPnet [online]. Available from URL: http//hcupnet.ahrq. gov [Accessed 2007 May 31]
49. McCormmick M. Infusion billing update: 2006 opportunities to ensure proper reimbursement and program success [online]. Available from URL: http://www.aan.com/professionals/coding/pdfs/aan-infusion-billing-06.pdf [Accessed 2007 Apr 6]
50. Ingenix Inc. The 2007 essential RBRVS: a comprehensive listing of RBRVS values for CPT and HCPCS codes. Salt Lake City (UT): Ingenix, Inc, 2006
51. Lichtenberg FR. Availability of new drugs and ability to work. J Occup Environ Med 2005; 47 (4): 373-380
52. Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work 2006; 27 (2): 143-151
53. US Department of Labor, Bureau of Labor and Statistics. Employer costs for employee compensation, March 2007 [online]. Available from URL: http://www.bls.gov/ncs/ect/home.htm [Accessed 2007 Jun 21]
54. Hoyert DL, Heron MP, Murphy SL, et al. Deaths: final data for 2003. National Vital Statistics Reports Vol. 54, no.13. Hyattsville (MD): National Center for Health Statistics, 2006
55. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in northeast Scotland. J Neurol Neurosurg Psychiatry 1987; 50 (5): 523-531
56. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line. In: Sloan FA, editor. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995
57. Eichler H, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds disease. Value Health 2004; 7 (5): 518-528
58. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342
59. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 2004; 18 (9): 561-574